Scancell Holdings plc (SCNLF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -11.93 Million GBP | -478.01% |
| 2022 | -2.06 Million GBP | 86.66% |
| 2021 | -15.47 Million GBP | -181.09% |
| 2020 | -5.5 Million GBP | 2.16% |
| 2019 | -5.62 Million GBP | -34.16% |
| 2018 | -4.19 Million GBP | -18.32% |
| 2017 | -3.54 Million GBP | -37.23% |
| 2016 | -2.58 Million GBP | -6.98% |
| 2015 | -2.41 Million GBP | -8.62% |
| 2014 | -2.22 Million GBP | -16.88% |
| 2013 | -1.9 Million GBP | -441.43% |
| 2012 | 557.05 Thousand GBP | 133.78% |
| 2011 | -1.64 Million GBP | 5.07% |
| 2010 | -1.73 Million GBP | -120.99% |
| 2009 | -786 Thousand GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.27 Million GBP | 85.47% |
| 2024 Q2 | -1.27 Million GBP | 0.0% |
| 2023 Q3 | -4.38 Million GBP | -38.5% |
| 2023 FY | -11.93 Million GBP | -478.01% |
| 2023 Q1 | -2.47 Million GBP | 53.0% |
| 2023 Q2 | -3.16 Million GBP | -27.76% |
| 2023 Q4 | -8.77 Million GBP | -100.0% |
| 2022 Q2 | 3.2 Million GBP | 100.0% |
| 2022 FY | -2.06 Million GBP | 86.66% |
| 2022 Q4 | -5.27 Million GBP | -35.6% |
| 2022 Q3 | -3.88 Million GBP | -221.23% |
| 2022 Q1 | 1.6 Million GBP | 113.8% |
| 2021 Q2 | -3.85 Million GBP | -100.0% |
| 2021 Q4 | -11.62 Million GBP | -100.0% |
| 2021 Q3 | -5.81 Million GBP | -50.64% |
| 2021 Q1 | -1.92 Million GBP | 35.66% |
| 2021 FY | -15.47 Million GBP | -181.09% |
| 2020 FY | -5.5 Million GBP | 2.16% |
| 2020 Q3 | -1.49 Million GBP | 40.27% |
| 2020 Q4 | -2.99 Million GBP | -100.01% |
| 2020 Q2 | -2.5 Million GBP | -99.99% |
| 2020 Q1 | -1.25 Million GBP | -5.26% |
| 2019 Q1 | -1.62 Million GBP | -49.48% |
| 2019 FY | -5.62 Million GBP | -34.16% |
| 2019 Q2 | -1.62 Million GBP | 0.0% |
| 2019 Q3 | -1.19 Million GBP | 26.54% |
| 2019 Q4 | -1.19 Million GBP | 0.0% |
| 2018 Q2 | -1.01 Million GBP | 0.0% |
| 2018 Q4 | -1.08 Million GBP | 0.0% |
| 2018 Q1 | -1.01 Million GBP | -10.94% |
| 2018 FY | -4.19 Million GBP | -18.32% |
| 2018 Q3 | -1.08 Million GBP | -7.24% |
| 2017 Q4 | -912.2 Thousand GBP | 0.0% |
| 2017 Q1 | -860.28 Thousand GBP | -22.17% |
| 2017 Q2 | -860.28 Thousand GBP | 0.0% |
| 2017 Q3 | -912.2 Thousand GBP | -6.04% |
| 2017 FY | -3.54 Million GBP | -37.23% |
| 2016 FY | -2.58 Million GBP | -6.98% |
| 2016 Q2 | -587.48 Thousand GBP | 0.0% |
| 2016 Q3 | -704.15 Thousand GBP | -19.86% |
| 2016 Q4 | -704.15 Thousand GBP | 0.0% |
| 2016 Q1 | -587.48 Thousand GBP | -9.33% |
| 2015 Q2 | -669.95 Thousand GBP | 0.0% |
| 2015 Q3 | -537.35 Thousand GBP | 19.79% |
| 2015 FY | -2.41 Million GBP | -8.62% |
| 2015 Q1 | -669.95 Thousand GBP | -29.41% |
| 2015 Q4 | -537.35 Thousand GBP | 0.0% |
| 2014 Q3 | -517.69 Thousand GBP | 12.82% |
| 2014 Q1 | -593.78 Thousand GBP | -21.31% |
| 2014 Q4 | -517.69 Thousand GBP | 0.0% |
| 2014 FY | -2.22 Million GBP | -16.88% |
| 2014 Q2 | -593.78 Thousand GBP | 0.0% |
| 2013 Q4 | -489.46 Thousand GBP | 0.0% |
| 2013 FY | -1.9 Million GBP | -441.43% |
| 2013 Q3 | -489.46 Thousand GBP | 0.0% |
| 2012 FY | 557.05 Thousand GBP | 133.78% |
| 2011 FY | -1.64 Million GBP | 5.07% |
| 2010 FY | -1.73 Million GBP | -120.99% |
| 2009 FY | -786 Thousand GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 84.077% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -81.505% |
| SQZ Biotechnologies Company | -79.46 Million USD | 84.979% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 122.53% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 118.326% |
| Mesoblast Limited | -87.95 Million USD | 86.43% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -555.634% |
| Genus plc | 7.9 Million USD | 251.089% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -9.588% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -221.705% |
| Marizyme, Inc. | -65.34 Million USD | 81.734% |
| ContraFect Corporation | -65.15 Million USD | 81.68% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -34.962% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -144.287% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -590.959% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -312.669% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -48.095% |
| MultiCell Technologies, Inc. | -380.07 USD | -3140374.123% |
| Accustem Sciences Inc. | -3.74 Million USD | -218.598% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 76.909% |
| EV Biologics, Inc. | -1.26 Million USD | -841.968% |
| Q BioMed Inc. | -2.05 Million USD | -481.65% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -219.743% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1787.392% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -401.329% |
| Biomind Labs Inc. | -1.21 Million USD | -882.938% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -10.54 Million USD | -13.159% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -51.029% |
| Skye Bioscience, Inc. | -37.64 Million USD | 68.293% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -450.093% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -79600.855% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -70.933% |
| IMV Inc. | -36.48 Million USD | 67.286% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 24.796% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -105.183% |
| GB Sciences, Inc. | -1.36 Million USD | -776.566% |
| Alpha Cognition Inc. | -13.77 Million USD | 13.335% |
| HST Global, Inc. | -146.21 Thousand USD | -8063.6% |
| CSL Limited | 2.64 Billion USD | 100.452% |
| Halberd Corporation | -79.67 Thousand USD | -14880.672% |
| Enzolytics Inc. | -2.17 Million USD | -448.32% |
| Resverlogix Corp. | -3.61 Million USD | -230.637% |
| Affymax, Inc. | -14.42 Million USD | 17.249% |
| SYBLEU INC | -180.3 Thousand USD | -6519.931% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -276.359% |
| argenx SE | -295.05 Million USD | 95.955% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 80.933% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 12279.592% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -200.428% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -294.431% |
| AVAX Technologies, Inc. | -6.41 Million USD | -86.103% |
| Zenith Capital Corp. | -10.59 Million USD | -12.646% |
| Genscript Biotech Corporation | -95.47 Million USD | 87.499% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -51255.305% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -187.896% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -19648.312% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 80.015% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -284.813% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1030.242% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -512.338% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -212.543% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -495.278% |
| BioStem Technologies, Inc. | -8.48 Million USD | -40.705% |
| ONE Bio Corp. | 8.67 Million USD | 237.565% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -2604.313% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -793.794% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -580.203% |
| Agentix Corp. | -1.37 Million USD | -768.571% |
| LadRx Corporation | 400.44 Thousand USD | 3080.699% |
| Cell Source, Inc. | -5.32 Million USD | -124.31% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2772.829% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1266.185% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1266.185% |
| NovAccess Global Inc. | -4.76 Million USD | -150.273% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 272.371% |
| Itoco Inc. | -1.86 Million USD | -538.632% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -168.675% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -615.159% |
| Kadimastem Ltd | -3.3 Million USD | -260.888% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -4265.733% |
| CytoDyn Inc. | -49.84 Million USD | 76.052% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -15002.552% |
| Mobile Lads Corp. | -2.26 Million USD | -427.373% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -5132.173% |
| Qrons Inc. | -789.34 Thousand USD | -1412.136% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1167.725% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -471.735% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1070.196% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -640.108% |
| International Stem Cell Corporation | -131 Thousand USD | -9011.45% |
| Bioxytran, Inc. | -4.28 Million USD | -178.878% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -21892.925% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -371.733% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 75.171% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -464.617% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1428.518% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -276.768% |
| Neutra Corp. | -233.46 Thousand USD | -5012.544% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 41.176% |
| PureTech Health plc | -65.69 Million USD | 81.832% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 43.874% |
| IXICO plc | -1.17 Million USD | -913.243% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -20.238% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 79.107% |
| CSL Limited | 2.64 Billion USD | 100.452% |
| Cellectis S.A. | -103.17 Million USD | 88.431% |